Getlabs’ Post

A growing number of people around the world are struggling with serious diseases – including diabetes, heart disease, and cancer. Mary Helen Black (VP, Head of Human Genomics at Foresite Labs) is working at the intersection between tech and healthcare. She said: “...we now know that we can use genetic information to not only find better treatments for these diseases, but also to discern which drug is the right one to take at the right time given a person's genetic background.” Read our full interview with Black to learn more about human genomics and precision therapeutics - https://bit.ly/45mia5y #LEAP24 #techinnovation #healthtech

Together, the Jeffrey Modell Foundation and Veritas are committed to making #genetic sequencing accessible to suspected Primary Immunodeficiency patients worldwide through the “Jeffrey's Insights” program. This collaboration spans six continents, 89 countries, 415 Jeffrey Modell Centers and 930 dedicated physicians. #PrimaryImmunodeficiency (PI) refers to a group of nearly 500 disorders of the immune system that are chronic, serious, and sometimes life-threatening. Early detection through genetic sequencing is crucial, as it can lead to life-saving interventions and #treatment strategies. However, access to genetic sequencing is challenging for many people worldwide. The alliance between the Jeffrey Modell Foundation and Veritas is more than just a partnership: it is a collaborative effort to provide #patients with proper diagnoses, treatment, and overall improved #quality of life.

𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 𝐢𝐬 𝐩𝐚𝐫𝐭𝐢𝐜𝐮𝐥𝐚𝐫𝐥𝐲 𝐜𝐫𝐮𝐜𝐢𝐚𝐥 𝐢𝐧 𝐩𝐞𝐝𝐢𝐚𝐭𝐫𝐢𝐜𝐬 𝐛𝐞𝐜𝐚𝐮𝐬𝐞 𝐜𝐡𝐢𝐥𝐝𝐫𝐞𝐧 𝐚𝐫𝐞 𝐧𝐨𝐭 𝐬𝐢𝐦𝐩𝐥𝐲 “𝐬𝐦𝐚𝐥𝐥 𝐚𝐝𝐮𝐥𝐭𝐬” By studying the genetic makeup of pediatric patients, researchers at Rady Children's Institute for Genomic Medicine are working to determine the most effective treatments for each individual child. This personalized approach can lead to better outcomes, fewer side effects, and faster recovery times. One exciting area of research at the institute is in the treatment of rare genetic disorders. By sequencing the genomes of children with these disorders, researchers can identify the underlying genetic mutations causing the condition. This information can then be used to develop targeted therapies that address the root cause of the disease, rather than just treating the symptoms. The work being done at Rady Children's Institute for Genomic Medicine is revolutionizing pediatric medicine. By taking a precision medicine approach, researchers are able to provide personalized care to children tailored to their unique genetic makeup, leading to better outcomes and improved quality of life. #Pediatrics #PrecisionMedicine #PersonalizedCare

🧬 Dr. Heidi Rehm from the Massachusetts General Hospital discusses a breakthrough in rare disease diagnostics: the power of affordable genomic sequencing.    🔬 With the ability to sequence entire genomes at a fraction of the cost, clinicians can sequence entire genomes, unlocking faster, more accurate diagnoses for rare disease patients and opening doors to novel discoveries.    👉 Watch the full webinar "Advocacy in rare disease: Driving Advances in Technology", in partnership with Science Magazine : https://lnkd.in/d6vMJsjc   #RareDisease #GenomicSequencing #RareDiseaseDiagnosis

📣 Come and catch me this week on our weekly webinar series at Sano Genetics 👋 I'll be talking all about how the #precisionmedicine landscape is changing and how I see the industry moving forwards over the next decade. 🧬 Before it does though, we need to solve a few major problems: 1. The patient experience in clinical trials, to put it bluntly... sucks - and retention rates are at an all time low. 2. Patient recruitment is already hard enough for 'non-precision' medicine assets - precision medicine trials probably require a re-think of how we tackle patient-finding. 3. Global trials that involve complex biomarker or genetic testing programs become unwieldy for clinical operations teams and trial sites that are already overburdened. Empowering patients and helping sponsors move faster and reduce costs are not mutually exclusive objectives. We think we have a pretty snazzy solution for you. Sign up at the link below to hear some more of my musings:

Excited to share my latest article on the groundbreaking advancements in genomic medicine 🧬. Researching for this piece and exploring the endless possibilities associated with genomic medicine felt like glimpsing into the future, where medical healthcare will be revolutionized, potentially averting much suffering. Although it seems like a far-fetched reality at the moment, it's a goal we're gradually working towards and is achievable. Learn more about it in this featured piece on WEmpower Pakistan. #genomicmedicine #healthcareinnovation

Jeffrey's Insights: 1134 patients tested and more than 12567 P/LP/VUS/risk variants have been found to date. The Jeffrey Modell Foundation together with Veritas, brings #geneticsequencing to suspected Primary Immunodeficiency patients worldwide via "Jeffrey's Insights" program. We have corroborated the clinical efficiency of NGS for IP, which contributes at a high rate to the alteration of clinical diagnosis and change in disease management due to genetic sequencing results. More than a partnership, the Jeffrey Modell Foundation and Veritas join forces for patients: better diagnoses, better treatment, better lives.

This document reports on insights from two multi-regional expert meetings discussing access issues in the treatment pathway involving the #BRCA test for #breastcancer. Experts suggest updating AIOM guidelines, correcting clinicians' behaviors, and reorganizing Integrated Care Pathways to improve rapid access to treatments. Updating access pathways to genetic tests is crucial, but it may present organizational and economic challenges for regions and cancer networks, aiming to enhance service quality provided by the #NationalHealthService. | https://ow.ly/MeST50SiR6o

If you couldn't join us live for our recent webcast on "VarSeq 2.5.0: VSClinical AMP Workflow From the User Perspective," don't worry. The recording is now available! Dive into the latest advancements in genomic data analysis and see how these tools can impact your work. Watch it here: https://bit.ly/3GqH3RP Don't miss this opportunity to stay at the forefront of genomic research! #Genomics #HealthcareInnovation #VarSeq #Webcast #AMP #AMPWorkflow

The enthusiasm surrounding the potential of DNA testing for answering life's big health questions has seen highs and lows. A decade ago, spurred by celebrity endorsements and TV shows like "Finding Your Roots," many believed that DNA tests could unlock secrets of ancestry and health predispositions. Angelina Jolie's public disclosure about her genetic risk for cancer and subsequent preventive surgery heightened interest in DNA testing's health implications. Anne Wojcicki, CEO of 23andMe, aimed to democratize DNA testing by making it affordable and creating a massive genetic data repository to aid research and health longevity. Despite initial excitement, including partnerships with Big Pharma and ventures into telehealth, 23andMe struggled to integrate into mainstream healthcare and has yet to turn a profit. The challenges stem not from physician resistance alone but from the limited practical utility of genetic testing. Most genetic insights offer little more than ancestral trivia, and while individual genes like BRCA can predict certain health risks, complex diseases like heart disease involve many genes and are heavily influenced by lifestyle. Recent ventures by 23andMe, such as the Total Health subscription, aim to provide comprehensive health assessments combining genetic data with blood tests and clinical consultations. However, the uptake has been modest, and the company faces financial pressures, with its stock value dropping significantly. The broader scientific community remains skeptical about the widespread utility of genetic data for predicting and preventing diseases. While genetic testing has enabled some advances in understanding and treating rare genetic conditions, its impact on common diseases and overall health management is limited. As the story around DNA testing shifts from a revolutionary tool to a more supplementary one, the industry is grappling with the reality of high expectations unmet by complex genetic realities. #DNARevolution #23andMe #GeneticTesting #HealthcareInnovation #AncestryDNA #PreventiveHealth #BiotechTrends